| abstract |
Stable pharmaceutical compositions of decarboethoxyloratadine (DCL), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are described. The compositions are formulated to avoid incompatibility between DCL and reactive excipients such as lactose and other mono- and disaccharides. The compositions described include lactose-free, non-hygroscopic and stable anhydrous pharmaceutical compositions of DCL. |